Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharma company NPS Pharmaceuticals
So what: EVOLVE, which stands for Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events, could have expanded the market for Sensipar and Mimpara. Investors following NPS know that these are key drugs for NPS in its partnership and licensing agreement with Amgen. The news isn't really a big deal for Amgen and its shareholders since it wouldn’t have had a huge upside impact for that massive company, but the gain would have been much more significant for the smaller NPS.
Now what: The calculus that investors should be doing today is figuring out how much upside from EVOLVE they believe was already baked into NPS' stock price. If the stock hadn't been priced for a huge gain from a positive outcome from EVOLVE, the double-digit sell-off today could very well be an overreaction.
Want to keep up to date on these stocks?
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.